The COVID-19 pandemic has affected many aspects of healthcare. Dr. Cuevas was apart of a study that showed the impact the pandemic had on research, specifically the POLARIS study. Researchers concluded that about 1/3 of clinical sites will experience an impact with clinical trials and that telehealth may be a method to mitigate these effects. Click the link below for more information.
FDA APPROVES G1 THERAPEUTICS’ COSELA™ (TRILACICLIB):
THE FIRST AND ONLY MYELOPROTECTION THERAPY TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION
St. Louis Magazine 2020 Best Doctors
Dr. Daniel Cuevas, Dr. Craig Hildreth and Dr. Giancarlo Pillot are featured in St. Louis Magazine’s 2020 Best Doctors issue! Year after year our physicians are voted as some of St. Louis’s best doctors for providing exceptional care to our patients!
New Study finds a drop in the mortality rate of NSCLC patients
A new study by the researchers at the National Cancer Institute suggests a drop in Non-Small Cell Lung Cancer mortality rates due to treatment advances in conjunction with a reduction in incidence. Please click here to read the entire article.
Another study did a Progression-Free Survival Subgroup Analysis of Olaparib Maintenance Therapy in Advanced BRCA-Mutated Ovarian Cancer patients
In an analysis from the SOLO-1 trial reported in the Journal of Clinical Oncology, DiSilvestro et al found that olaparib vs placebo maintenance therapy after first-line platinum-based therapy in patients with advanced BRCA-mutated ovarian cancer significantly improved progression-free survival in predefined patient subgroups. Please click here to read the entire article.
Staying safe and figting cancer during covid!
See picture of Dr. Cuevas and his patient at our north county location. We have measures in place to keep our patients as safe as possible during this covid-19 crisis.
Our New Community Service Page
You can see the community projects we are involved with in our new Community Service Page.
Castle Connolly Top Doctors Award
Dr. Hildreth received the Castle Connolly Top Doctors award again this year. To receive this award, physicians nominate other physicians that they feel are the most outstanding in their medical specialties and are among the best in their region or country. The Castle Connolly physician-led research team then selects the winners based on nominations.
He first received this award in 2006 and then annually since 2013. Way to go Dr. Hildreth!
National ION Meeting, November 2nd 2019
Carol Riley, our practice manager, was asked to speak at the National ION meeting regarding how St. Louis Cancer Care is putting precision medicine into practice.
Celebrated Halloween 2019 with a costume contest to add some festive fun to our treatment room for our patients. See attached pictures --
Latest News in Research
St. Louis Cancer Care physicians and staff are proud to announce a partnership with ALCMI, (voiced as “Alchemy”) an international consortium dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. In addition, all of our St. Louis Cancer Care offices are also participating in LIBERTI; a study designed to investigate the role of circulating tumor DNA (ctDNA) from liquid biopsy in early stage non-small cell lung cancer.
Feel free to contact our office and clinical research nurse Kelli Martin, RN at any time for more information. (314)291-3312.
Keeping Down the Cost of Medications for our Patients
St. Louis Cancer Care strives to dispense our patients chemotherapy medications to them directly rather than use specialty pharmacies owned by pharmacy benefit managers. This keeps your costs down and allows your oncology team to more closely monitor your medication and its side effects. Click here to read the article.
Killing Medicare Part D Rebate Rule a Huge Gift to Pharmacy Benefit Managers (PBMs)
The Trump Administration is withdrawing a proposed rule to eliminate rebates which would have lowered drug prices and in turn benefited patients with cancer. Because of this, your drug prices are likely to increase. Here is the link to the article from Community Oncology Alliance (COA). You may want to reach out to your state senator/representative to give your feedback.
Click here to read the article.
Last year we found over $400,000 in patient assistance for our patients that are getting both oral and IV chemotherapy.
Kelli Martin, RN, BSN, Certified Clinical Research Coordinator and
J. Daniel Cuevas, MD, Partner and Director of Clinical Research